BIIB Biogen

At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.
Company profile
Ticker
BIIB
Exchange
Website
CEO
Michel Vounatsos
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BIOGEN IDEC INC, BIOGEN IDEC INC., IDEC PHARMACEUTICALS CORP / CA, IDEC PHARMACEUTICALS CORP / DE
SEC CIK
Corporate docs
IRS number
330112644
BIIB stock data
()
News
The Week Ahead In Biotech: Johnson & Johnson, Biogen Earnings, Neurology Conference And IPOs
17 Apr 21
Biogen Announces China Has Approved TECFIDERA For The Treatment Of Relapsing Multiple Sclerosis
15 Apr 21
Biogen Says To Present Trial Design Of Aducanumab EMBARK Re-Dosing Study In Poster Session At 2021 Virtual AAN Annual Meeting On April 17-22, 2021
14 Apr 21
Sage-Biogen Essential Tremor Candidate Hits Primary Endpoint Goal, But 38% Of People Drop Out
12 Apr 21
Wedbush Maintains Neutral on Biogen, Raises Price Target to $245
12 Apr 21
Press releases
New Data at AAN 2021 from Across Biogen's MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis
16 Apr 21
Biogen Grows Presence in China with the Approval of TECFIDERA® (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
15 Apr 21
Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021
14 Apr 21
Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint
12 Apr 21
Biogen Announces Two New Nominees for Election to Board of Directors
9 Apr 21
Calendar
3 Feb 21
18 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from Biogen earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.33B | 1.33B | 1.33B | 1.33B | 1.33B | 1.33B |
Cash burn (monthly) | 297.87M | 131.88M | 110.2M | (positive/no burn) | 122.37M | (positive/no burn) |
Cash used (since last report) | 1.07B | 475.57M | 397.4M | n/a | 441.28M | n/a |
Cash remaining | 257.03M | 855.63M | 933.8M | n/a | 889.92M | n/a |
Runway (months of cash) | 0.9 | 6.5 | 8.5 | n/a | 7.3 | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Feb 21 | Alexander Susan H | RSU Common Stock | Grant | Aquire A | No | No | 0 | 10,870 | 0 | 10,870 |
18 Feb 21 | Alphonse Galdes | RSU Common Stock | Grant | Aquire A | No | No | 0 | 10,870 | 0 | 10,870 |
18 Feb 21 | Ginger Gregory | RSU Common Stock | Grant | Aquire A | No | No | 0 | 10,150 | 0 | 10,150 |
18 Feb 21 | Chirfi Guindo | RSU Common Stock | Grant | Aquire A | No | No | 0 | 14,500 | 0 | 14,500 |
18 Feb 21 | Kramer Robin | RSU Common Stock | Grant | Aquire A | No | No | 0 | 2,900 | 0 | 2,900 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
84.3% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 1022 |
Opened positions | 167 |
Closed positions | 153 |
Increased positions | 272 |
Reduced positions | 414 |
13F shares |
Current |
---|---|
Total value | 31.57B |
Total shares | 128.45M |
Total puts | 5.83M |
Total calls | 5.76M |
Total put/call ratio | 1.0 |
Largest owners |
Shares | Value |
---|---|---|
Primecap Management | 15.82M | $3.87B |
BLK Blackrock | 13.42M | $3.29B |
Vanguard | 11.9M | $2.91B |
STT State Street | 6.99M | $1.71B |
Wellington Management | 5.78M | $1.42B |
Clearbridge Advisors | 3.6M | $881.17M |
Renaissance Technologies | 3.04M | $743.83M |
JPM JPMorgan Chase & Co. | 2.91M | $713.04M |
Geode Capital Management | 2.76M | $674.21M |
NTRS Northern Trust | 2.2M | $538.93M |
Financial report summary
?Competition
Spectrum Pharmaceuticals • Sarepta Therapeutics • Alexion Pharmaceuticals • Sangamo Therapeutics • X.T.L. Biopharmaceuticals • Seagen • Cytokinetics • Cassava Sciences • PTC Therapeutics • Alterity TherapeuticsRisks
- We are substantially dependent on revenues from our products.
- Our long-term success depends upon the successful development of new products and additional indications for our existing products.
- If we fail to compete effectively, our business and market position would suffer.
- We depend on relationships with collaborators, joint venture partners and other third parties for revenues, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates, which are outside of our full control.
- Our results of operations may be adversely affected by current and potential future healthcare reforms.
- Our success in commercializing biosimilars developed by Samsung Bioepis is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If Samsung Bioepis is unsuccessful in such activities, we may not realize the anticipated benefits of our investment in Samsung Bioepis.
- Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.
- Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied.
- Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.
- The illegal distribution and sale by third parties of counterfeit or unfit versions of our products or stolen products could have a negative impact on our reputation and business.
- The increasing use of social media platforms presents new risks and challenges.
- If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed.
- The ongoing COVID-19 pandemic may, directly or indirectly, adversely affect our business, results of operations and financial condition.
- A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.
- Management and key personnel changes may disrupt our operations, and we may have difficulty retaining key personnel or attracting and retaining qualified replacements on a timely basis for management and other key personnel who may leave the Company.
- If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.
- Our sales and operations are subject to the risks of doing business internationally.
- We are building a large-scale biologics manufacturing facility, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.
- Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenues.
- Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts.
- Our operating results are subject to significant fluctuations.
- Our investments in properties may not be fully realized.
- Our investment portfolio is subject to market, interest and credit risk that may reduce its value.
- There can be no assurance that we will continue to repurchase shares or that we will repurchase shares at favorable prices.
- We may not be able to access the capital and credit markets on terms that are favorable to us.
- Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business.
- Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.
Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
Abeta, AccessAbility, ACR, adjunctive, aflibercept, African, AHEAD, Aid, alpha, amortizable, andMovement, annul, Annulment, antigen, app, Armata, array, arthritisAxial, arthritisCrohn, arthritisJuvenile, arthritisPsoriasisPaediatric, arthritisPsoriatic, arthritisTwo, attached, ATV, Bachelor, back, begun, BioDiversity, Black, bolster, border, caliber, CCPA, child, childcare, chlorambucil, climate, CLLFollicular, coach, colitisAnkylosing, colitisPaediatric, colitisUveitisPaediatric, commentary, compassionate, compliant, condensed, contractor, cope, DAC, deepen, deeply, degeneration, Denali, dendritic, diabetic, diseasePaediatric, diseaseUlcerative, DISH, dispensed, dispensing, divergent, DME, EchoStar, elevated, email, EMBARK, empower, empowering, endothelial, English, entirety, equitable, equitably, essential, estoppel, ethnic, expressed, expression, feel, female, fidelity, finger, flat, fossil, FranceGermany, FranceGermanyItaly, Georgetown, globe, great, guide, hacking, Hammersmith, headache, Headspace, heard, HFMSE, highest, home, humanitarian, IGNITE, IM, Immersing, immunogenicity, implication, incumbent, indirectly, inspired, Intelsat, intermediate, intolerance, invaluable, IQVIA, isolation, job, knowledge, lab, Lancet, Latinx, length, LGBTQ, lowest, lymphomaCLL, lymphomaCLLRheumatoid, lymphomaIn, MAA, macular, magnetic, mcdonnell, MCG, MDD, meditation, mentoring, mobile, modestly, morale, Mosaic, NaN, nausea, neovascular, nm, nonrecurring, Notably, occlusion, ourIMPACT, pandemic, paramount, Partnership, PDUFA, Peripheral, philosophy, plasmacytoid, Portuguese, postpartum, PPD, proactive, problem, Prolonged, psoriasisPaediatric, pulse, racial, racism, ranibizumab, ReachOUT, recharging, redosing, refraining, refreshed, release, reluctance, remyelination, renowned, resonance, retinopathy, Retreat, reward, rigor, route, sage, satellite, sc, shape, shelter, Shilpa, similarly, slowdown, solution, Spanish, spondylitisPsoriatic, spondyloarthritisPlaque, spondyloarthritisPsoriatic, spread, statutorily, strain, suppurativaAdolescent, suppurativaCrohn, supraneuclear, survey, Taiwan, teen, toferson, transport, travel, tremor, trust, ulcerative, unacceptable, underrepresented, underway, unprecedented, User, vascular, vast, Vehicle, vein, virtual, volunteering, Waltham, wet, workplace, zinc, zuranolone
Removed:
AAV, abroad, AD, afforded, ALPROLIX, AmerisourceBergen, Antihemophilic, Article, Aurobindo, Bayer, Beacon, BENEPALITM, BETASERON, Carlyle, cerebral, complaint, confirmed, Congressional, continuation, cooperating, coupon, curtail, decided, declaratory, decreased, depart, dismissed, disproportionately, Duke, ELOCTA, ELOCTATE, EMD, enabling, evolution, exit, EXTAVIA, FAMPYRATM, fatal, Fc, finalization, FLIXABITM, floating, formally, founder, fulminant, FUMADERMTM, Fusion, genetic, glatiramer, Glenmark, glibencamide, hour, immunomodulation, IMRALDITM, interference, interpreting, invalidity, Italia, Jersey, Johnson, joined, learned, LIBOR, liver, lumbosacral, macroeconomic, marketer, McKenzie, McKesson, Milan, Monomoy, mortality, Neurocrine, notified, observational, outflow, partnering, Paul, Pennsylvania, placebo, PLSR, prove, radiculopathy, rapidly, REBIF, referendum, Remedy, repayment, replacement, restructuring, ruling, Sawai, score, SEC, seller, separately, Serono, Shipla, staffing, stake, succeeding, swelling, tenure, tool, transitioning, Treasurer, unknown, unrecorded, Vermont, voluntarily, wage, weak, Zug
Financial reports
10-K
2020 FY
Annual report
3 Feb 21
10-Q
2020 Q3
Quarterly report
21 Oct 20
10-Q
2020 Q2
Quarterly report
22 Jul 20
10-Q
2020 Q1
Quarterly report
23 Apr 20
10-K
2019 FY
Annual report
6 Feb 20
10-Q
2019 Q3
Quarterly report
22 Oct 19
10-Q
2019 Q2
Quarterly report
23 Jul 19
10-Q
2019 Q1
Quarterly report
24 Apr 19
10-K
2018 FY
Annual report
6 Feb 19
10-Q
2018 Q3
Quarterly report
23 Oct 18
Current reports
8-K
Biogen Announces Two New Nominees for Election to Board of Directors
9 Apr 21
8-K
Other Events
15 Feb 21
8-K
Biogen Announces Private Exchange Offer
4 Feb 21
8-K
Biogen Reports Fourth Quarter and Full Year 2020 Results
3 Feb 21
8-K
Biogen Reports Q3 2020 Results
21 Oct 20
8-K
Departure of Directors or Certain Officers
21 Sep 20
8-K
Biogen Reports Q2 2020 Revenues of $3.7 Billion
22 Jul 20
8-K
Biogen Names Michael McDonnell as Executive Vice President and Chief Financial Officer
21 Jul 20
8-K
Other Events
18 Jun 20
8-K
Submission of Matters to a Vote of Security Holders
5 Jun 20
Registration and prospectus
424B2
Prospectus for primary offering
28 Apr 20
FWP
Free writing prospectus
27 Apr 20
424B2
Prospectus for primary offering
27 Apr 20
S-3ASR
Automatic shelf registration
24 Apr 20
S-8
Registration of securities for employees
15 Jun 17
424B2
Prospectus for primary offering
10 Sep 15
FWP
Free writing prospectus
10 Sep 15
424B2
Prospectus for primary offering
9 Sep 15
S-3ASR
Automatic shelf registration
7 Sep 15
S-8
Registration of securities for employees
25 Jun 15
Proxies
PRE 14A
Preliminary proxy
9 Apr 21
DEFA14A
Additional proxy soliciting materials
9 Apr 21
DEFA14A
Additional proxy soliciting materials
20 Apr 20
DEF 14A
Definitive proxy
20 Apr 20
DEFA14A
Additional proxy soliciting materials
24 May 19
DEFA14A
Additional proxy soliciting materials
30 Apr 19
DEF 14A
Definitive proxy
30 Apr 19
DEFA14A
Additional proxy soliciting materials
29 Apr 19
PX14A6G
Letter to shareholders
3 May 18
DEFA14A
Additional proxy soliciting materials
27 Apr 18
Other
UPLOAD
Letter from SEC
22 Jul 18
UPLOAD
Letter from SEC
24 May 17
CORRESP
Correspondence with SEC
9 May 17
UPLOAD
Letter from SEC
2 May 17
CORRESP
Correspondence with SEC
3 Apr 17
UPLOAD
Letter from SEC
22 Mar 17
NO ACT
No action letter
22 Feb 17
CT ORDER
Confidential treatment order
28 Mar 16
CT ORDER
Confidential treatment order
28 Apr 13
UPLOAD
Letter from SEC
1 Jul 12
Ownership
4
BIOGEN / Michel Vounatsos ownership change
22 Feb 21
4
BIOGEN / Alfred Sandrock ownership change
22 Feb 21
4
BIOGEN / MICHAEL R MCDONNELL ownership change
22 Feb 21
4
BIOGEN / Robin Kramer ownership change
22 Feb 21
4
BIOGEN / Chirfi Guindo ownership change
22 Feb 21
4
BIOGEN / Ginger Gregory ownership change
22 Feb 21
4
BIOGEN / Alphonse Galdes ownership change
22 Feb 21
4
BIOGEN / SUSAN H ALEXANDER ownership change
22 Feb 21
4
BIOGEN / Michel Vounatsos ownership change
17 Feb 21
4
BIOGEN / Alfred Sandrock ownership change
17 Feb 21
Patents
APP
Utility
Method for Treating Joint Damage
28 Jan 21
Methods of treating joint damage in a subject eligible for treatment are provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the subject in an amount effective to slow progression of the joint damage as measured by radiography.
GRANT
Utility
Formulations and methods for lyophilization and lyophilates provided thereby
21 Dec 20
The present invention provides compositions, methods for lyophilizing compounds and making pharmaceutical compositions, and kits providing solutions and lyophilized formulations of compounds.
APP
Utility
Compositions and Methods for Treating Synucleinopathies
2 Dec 20
Dosage regimens of anti-α-synuclein antibodies are provided.
GRANT
Utility
Methods for treating Alzheimer's disease
23 Nov 20
A method for treatment of a human patient for Alzheimer's disease (AD) comprises sequentially administering multiple doses of a recombinant, fully human, anti-amyloid beta monoclonal antibody to the patient.
APP
Utility
Process for Preparing Spiro Derivatives
14 Oct 20
The invention relates to a novel process for preparing Spiro derivatives, in particular 7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one, and to novel intermediates for use in said process along with processes for preparing said intermediates.
Transcripts
2020 Q4
Earnings call transcript
3 Feb 21
2020 Q3
Earnings call transcript
21 Oct 20
2020 Q2
Earnings call transcript
22 Jul 20
2020 Q1
Earnings call transcript
22 Apr 20
2019 Q4
Earnings call transcript
30 Jan 20
2019 Q3
Earnings call transcript
22 Oct 19
2019 Q2
Earnings call transcript
23 Jul 19
2019 Q1
Earnings call transcript
24 Apr 19
2018 Q4
Earnings call transcript
29 Jan 19
2018 Q3
Earnings call transcript
23 Oct 18
Reddit threads
ATNF finally set for a big Short Squeeze on Monday.. and a couple of false starts.. Friday finally held above $9.50 for the first time.
10 Apr 21
ATNF Short Squeeze may jump tmrw & best management team in entire Biotech industry.
8 Apr 21
Big Pharma companies are highly undervalued and underrated dividend stocks.
18 Mar 21
Using options trading as main source of income
12 Mar 21
My own mini ETF sorta portfolio
24 Feb 21
My own mini ETF stock picks (Daily Investing)
24 Feb 21
AGTC.. Biopharma Play with 100%+ upside
22 Feb 21
AGTC. Biopharma play with 100% upside! DD
22 Feb 21
Warren Buffett Quantitative Checklist - 5000+ Stocks Rated
22 Feb 21
Vlad's testimony in a nutshell
19 Feb 21